CAMP4 Therapeutics granted stock options to two new employees as an inducement for employment, aligning with Nasdaq regulations.
Quiver AI Summary
CAMP4 Therapeutics Corporation has announced the granting of non-qualified stock options to purchase 30,000 shares of its common stock to two new employees as an inducement for their employment. This grant, dated November 16, 2026, is in line with Nasdaq Listing Rule 5635(c)(4) and features an exercise price of $3.86 per share, matching the stock's closing price that day. The options have a ten-year term and will vest over four years, with 25% vesting after one year and the remainder in monthly installments, contingent upon the employees remaining with the company. CAMP4 focuses on developing RNA-targeting therapeutics to enhance gene expression and combat various genetic diseases, employing its RAP Platform® to create innovative treatment candidates for conditions related to protein deficiencies.
Potential Positives
- The grant of non-qualified stock options to newly hired employees indicates the company's commitment to attracting skilled talent, which is crucial for its growth and development in a competitive biopharmaceutical market.
- The stock options are tied to the company's common stock price, aligning the interests of new employees with those of shareholders, potentially enhancing company performance.
- The vesting schedule of the stock options over a four-year period encourages long-term commitment from the new employees, which can contribute to the stability and continuity of the company's workforce.
- The announcement reflects CAMP4's ongoing progress in its clinical-stage developments, which highlights the company's focus on innovative RNA-targeting therapeutics in the treatment of genetic diseases.
Potential Negatives
- The announcement of inducement grants for newly hired employees may raise concerns about the company's financial health and reliance on incentivizing new hires in a competitive market.
- Granting stock options to new employees could lead to dilution of existing shareholders’ equity if the options are exercised in the future.
- The reliance on performance-based stock options might signal that the company needs to ensure employee commitment and motivation, indicating potential challenges in attracting and retaining talent.
FAQ
What stock options were granted by CAMP4 Therapeutics?
CAMP4 granted non-qualified stock options to purchase 30,000 shares of common stock to two newly hired employees.
What is the exercise price for the stock options?
The exercise price for the stock options is $3.86, matching the closing price of CAMP4's stock on the grant date.
How long is the term for the granted stock options?
The term of the granted stock options is ten years from the date of grant.
What is the vesting schedule for the stock options?
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter.
What does CAMP4 Therapeutics specialize in?
CAMP4 specializes in developing regulatory RNA-targeting therapeutics to treat genetic diseases by restoring healthy protein levels.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CAMP Insider Trading Activity
$CAMP insiders have traded $CAMP stock on the open market 11 times in the past 6 months. Of those trades, 5 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $CAMP stock by insiders over the last 6 months:
- ANDREW J. SCHWAB has made 0 purchases and 5 sales selling 591,875 shares for an estimated $2,495,763.
- KELLY GOLD (Chief Financial Officer) has made 2 purchases buying 16,551 shares for an estimated $50,409 and 0 sales.
- RICHARD A YOUNG purchased 16,378 shares for an estimated $27,023
- YURI MARICICH (Chief Medical Officer) purchased 6,551 shares for an estimated $10,809
- JOSH MANDEL-BREHM (Chief Executive Officer) purchased 6,551 shares for an estimated $10,809
- DANIEL TARDIFF (Chief Scientific Officer) sold 1,738 shares for an estimated $8,272
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CAMP Hedge Fund Activity
We have seen 43 institutional investors add shares of $CAMP stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 2,229,239 shares (+113.7%) to their portfolio in Q3 2026, for an estimated $9,006,125
- TRAILS EDGE CAPITAL PARTNERS, LP added 1,692,639 shares (+87.6%) to their portfolio in Q3 2026, for an estimated $6,838,261
- STONEPINE CAPITAL MANAGEMENT, LLC added 1,396,627 shares (+100.5%) to their portfolio in Q3 2026, for an estimated $5,642,373
- VIVO CAPITAL, LLC added 1,337,543 shares (+31.5%) to their portfolio in Q3 2026, for an estimated $5,403,673
- IKARIAN CAPITAL, LLC added 912,906 shares (+inf%) to their portfolio in Q3 2026, for an estimated $3,688,140
- VANGUARD CAPITAL MANAGEMENT LLC added 612,810 shares (+40.0%) to their portfolio in Q3 2026, for an estimated $2,475,752
- 5AM VENTURE MANAGEMENT, LLC removed 591,875 shares (-10.1%) from their portfolio in Q3 2026, for an estimated $2,391,175
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$CAMP Analyst Ratings
Wall Street analysts have issued reports on $CAMP in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Raymond James issued a "Strong Buy" rating on 10/23/2026
- Needham issued a "Buy" rating on 10/15/2026
- Oppenheimer issued a "Outperform" rating on 10/05/2026
- Chardan Capital issued a "Buy" rating on 09/29/2026
- Piper Sandler issued a "Overweight" rating on 08/14/2026
To track analyst ratings and price targets for $CAMP, check out Quiver Quantitative's $CAMP forecast page.
$CAMP Price Targets
Multiple analysts have issued price targets for $CAMP recently. We have seen 6 analysts offer price targets for $CAMP in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Tiago Fauth from Raymond James set a target price of $10.0 on 10/23/2026
- Joseph Stringer from Needham set a target price of $8.0 on 10/15/2026
- Kostas Biliouris from Oppenheimer set a target price of $15.0 on 10/05/2026
- Keay Nakae from Chardan Capital set a target price of $6.0 on 09/29/2026
- Edward Tenthoff from Piper Sandler set a target price of $15.0 on 08/14/2026
- Anupam Rama from JP Morgan set a target price of $9.0 on 06/16/2026
Full Release
WATERTOWN, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on November 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 30,000 shares of the Company’s common stock to two newly hired employees of the Company, each as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).
The Inducement Grants each have a ten-year term and an exercise price per share of $3.86, which is equal to the closing price of CAMP4’s common stock as of the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. The Inducement Grants were granted pursuant to, and are subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable non-qualified stock option agreement.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
[email protected]
Media:
Sofia Bermudez
LifeSci Communications
[email protected]